ALCMI Providing Samples for Validation of Exosome Dx's Lung Cancer Tests | GenomeWeb

NEW YORK(GenomeWeb) – Exosome Diagnostics today announced a collaboration with the Addario Lung Cancer Medical Institute in which the ALCMI is providing samples from an ongoing clinical trial to help Exosome advance its plasma-based lung cancer mutation tests.

According to Exosome, the collaboration will support the validation of its ALK and EGFR T790M liquid biopsy diagnostics, which the company plans to launch this year as laboratory-developed tests. The work will also support future development of these assays as IVD kits, Exosome added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.